19 February 2015 – Seventeen neglected tropical diseases, such as dengue, leprosy or dracunculiasis (guinea-worm disease), currently affect low and...
Amivas Ireland Ltd., specialists in treatments for rare and neglected tropical diseases, including severe malaria, has announced the European Commission has granted approval for the Company to commercialize its lead product, Artesunate Amivas (artesunate), in EU/EEA.
The FDA on 19 March 2014 granted approval to Knight Therapeutics to market Impavido (miltefosine) as a treatment for cutaneous,...
Benznidazole was approved by the FDA to treat Chagas disease, using the Accelerated Approval pathway. The Accelerated Approval pathway allows...
Sanofi Pasteur, the vaccines division of Sanofi announced that its tetravalent Dengue Vaccine candidate demonstrated proof of efficacy against Dengue,...
The European Commission has granted marketing authorization for Dengvaxia, Sanofi's dengue vaccine. The marketing authorization follows the 18 October 2018,...
Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF 156, a next-generation antimalarial compound with...
Sanofi Pasteur, the vaccines division of Sanofi announced that the final landmark phase III efficacy study of its Dengue vaccine...
Sanofi Pasteur, the vaccines division of Sanofi has announced that the first of two pivotal Phase III efficacy studies with...
Sanofi Pasteur, the vaccines division of Sanofi has announced the publication in The Lancet of the detailed results of its...